Allostery Investments LP Takes Position in Gossamer Bio, Inc. (NASDAQ:GOSS)

Allostery Investments LP acquired a new stake in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 613,028 shares of the company's stock, valued at approximately $555,000. Gossamer Bio comprises about 0.6% of Allostery Investments LP's portfolio, making the stock its 24th largest position. Allostery Investments LP owned approximately 0.27% of Gossamer Bio at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Opti Capital Management LP purchased a new position in shares of Gossamer Bio in the fourth quarter valued at approximately $165,000. Smith Moore & CO. lifted its position in shares of Gossamer Bio by 32.7% during the 4th quarter. Smith Moore & CO. now owns 300,000 shares of the company's stock worth $271,000 after buying an additional 74,000 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Gossamer Bio by 1.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock valued at $1,123,000 after purchasing an additional 13,902 shares during the period. Geode Capital Management LLC raised its position in Gossamer Bio by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company's stock valued at $2,037,000 after purchasing an additional 38,084 shares during the last quarter. Finally, Monaco Asset Management SAM raised its stake in Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock valued at $4,859,000 after acquiring an additional 1,520,721 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company's stock.

Gossamer Bio Stock Up 0.5 %

Shares of NASDAQ:GOSS traded up $0.01 during mid-day trading on Wednesday, hitting $1.10. 299,839 shares of the company traded hands, compared to its average volume of 1,550,452. The firm has a market cap of $248.81 million, a P/E ratio of -3.42 and a beta of 1.82. Gossamer Bio, Inc. has a 52-week low of $0.50 and a 52-week high of $1.55. The firm's 50 day simple moving average is $1.06 and its 200 day simple moving average is $0.98. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.15). The firm had revenue of $9.38 million for the quarter, compared to analyst estimates of $7.02 million. On average, equities analysts anticipate that Gossamer Bio, Inc. will post -0.28 EPS for the current year.

Analyst Ratings Changes

GOSS has been the subject of several research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Gossamer Bio in a research report on Tuesday, March 18th. The Goldman Sachs Group cut their price objective on Gossamer Bio from $8.00 to $7.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. Finally, Wedbush restated an "outperform" rating and issued a $4.00 price objective on shares of Gossamer Bio in a research report on Friday, March 14th.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.